Aug 07, 2025 • Motley Fool
NEUTRAL
Protagonist ( PTGX ) Q2 Revenue Falls 26%
Protagonist Therapeutics ( NASDAQ:PTGX ) , a clinical-stage biotechnology company developing peptide-based therapies for blood and immune diseases, released second quarter results on August 6, 2025. The most significant news from the release was the company's continued advancement of its ...
Aug 06, 2025 • Zacks Commentary
NEUTRAL
Protagonist Therapeutics ( PTGX ) Reports Q2 Loss, Lags Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.77% and -46.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 22, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.
Jun 23, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Tango Therapeutics ( TNGX ) Moves 7.5% Higher: Will This Strength Last?
Tango Therapeutics (TNGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
May 12, 2025 • Zacks Commentary
NEUTRAL
J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study
Data from a late-stage study shows that treatment with JNJ's icotrokinra helps achieve significant skin clearance in hard-to-treat scalp and genital psoriasis.
May 09, 2025 • Benzinga
SOMEWHAT-BULLISH
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study - Protagonist Therapeutics ( NASDAQ:PTGX ) , Johnson & Johnson ( NYSE:JNJ )
77% of genital psoriasis patients saw clear/almost clear skin vs. 21% on placebo after 16 weeks. PN-881 showed 70x greater potency than secukinumab in vitro and effective reduction in skin inflammation in rat models.